Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B surface antigen messenger RNA (HBsAg mRNA)
- Target
- HBsAg mRNA
- Molecular classification
- Other (HBsAg mRNA is a viral messenger RNA encoding a structural protein)
01
Overview
Hepatitis B surface antigen messenger RNA (HBsAg mRNA) is the viral RNA transcript produced by the hepatitis B virus (HBV) from its S gene. The HBV genome encodes multiple mRNA species, including those that give rise to the large (L), middle (M), and small (S) forms of hepatitis B surface antigen (HBsAg), which together constitute the envelope proteins of the virus. These mRNAs are transcribed in infected hepatocytes and serve as templates for translation in the endoplasmic reticulum, after which the HBsAg proteins are processed and secreted. HBsAg mRNA is essential for viral assembly and propagation, but is not itself a therapeutic target in current clinical practice; rather, the HBsAg protein is the standard biomarker for diagnosis and monitoring of hepatitis B infection. Experimental therapies may target HBV mRNAs as part of RNA interference or antisense approaches.
- Other names
- Hepatitis B virus surface antigen mRNAHBV S gene mRNApreS/S mRNAL-HBsAg mRNAM-HBsAg mRNAS-HBsAg mRNA
02
Mechanism of action
Not directly applicable; experimental agents may degrade viral RNAs or hinder translation, reducing HBsAg protein synthesis
03
Biological functions
Template for translation of hepatitis B surface antigen proteins (envelope proteins of hepatitis B virus)Essential for the production of new HBV virions
04
Disease associations
Infection (chronic and acute hepatitis B)Cancer (correlated with hepatocellular carcinoma via HBV infection)
05
Safety considerations
None specifically for the RNA itself; safety concerns are more pertinent for interventions targeting viral RNA in hepatocytes (e.g., off-target effects, delivery efficiency)
06
Interacting drugs
None directly; some nucleic acid–targeted agents (e.g., RNA interference therapeutics) may target HBV mRNAs, but no drugs target specifically and solely \"HBsAg mRNA\"
07
Biomarkers
Not directly; instead, HBsAg protein is a primary biomarker for HBV infection and disease monitoring
Beyond the preview
Go deeper on Hepatitis B surface antigen messenger RNA (HBsAg mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatitis B surface antigen messenger RNA (HBsAg mRNA).